Hequan pharmaceutical new preparation production base has successfully passed the GMP certification of the European Drug Administration for the first time

March 27, 2019 / Meitong news agency / -- Hequan pharmaceutical, a subsidiary of Wuxi Wuxi Pharmaceutical Co., Ltd., announced that its pharmaceutical production base in Shanghai pilot free trade zone has successfully passed the GMP certification of the European drug administration This is the first time that Hequan pharmaceutical new preparation production base has passed this certification since it was put into operation at the end of 2018, which also shows that Hequan pharmaceutical preparation business has an international standard quality system and a good development trend Since the business integration with pharmaceutics Department of Wuxi apptec in 2017, Hequan pharmaceutical has been able to provide global partners with one-stop solutions from APIs to preparations, and realize the seamless connection of the entire chemical, production and control (CMC) industry chain In recent years, with hundreds of millions of tablet and capsule production lines being put into production in Wuxi and Shanghai pharmaceutical production bases, Hequan pharmaceutical has opened up the whole industrial chain of innovative drugs from pre clinical to commercialization for customers, and ushered in a number of clinical phase III and commercialization phase preparation projects Previously, the Shanghai Jinshan API production base and Changzhou API R & D and production base of Hequan Pharmaceutical Co., Ltd have successfully passed the FDA audit for many times As a leading enterprise in the field of global new drug cooperative research, development and production (cdmo), Hequan pharmaceutical industry has been adhering to the highest quality standards in the world for many years, and has become a supplier of innovative drug APIs and GMP advanced intermediates reviewed by the pharmaceutical regulatory departments of the United States, Europe, Canada, Switzerland, Australia, New Zealand and China "We are very proud to obtain the GMP certification of the European drug administration," said Ms Hao Mei, vice president of global quality of Hequan pharmaceutical "This is an important milestone of our integrated services We will continue to uphold the spirit of excellence and excellence, and provide the highest quality services to our global partners " "Quality is the lifeline and core competitiveness of the pharmaceutical industry The Shanghai Free Trade Zone pharmaceutical production base successfully passed the GMP certification of the European drug administration, which is another embodiment of Hequan pharmaceutical industry's adherence to the highest international quality standards We will take this as a new starting point, continue to deepen the whole industry chain, help partners accelerate the process of innovative drug listing, and benefit patients around the world " Chen minzhang, chief executive of Hequan pharmaceutical, said About Hequan Pharmaceutical Co., Ltd Hequan Pharmaceutical Co., Ltd is a subsidiary of Wuxi Pharmaceutical Co., Ltd which operates in both China and the United States It serves the life science industry and has excellent capability and technical platform for research and development and production of chemical innovative drugs As a leading enterprise in the field of global research, development and production of new drugs (cdmo), Hequan pharmaceutical is committed to providing global partners with one-stop solutions of high efficiency, flexibility and quality from API to preparations For more information, please visit the company's website: www.stapharma.com.cn about Wuxi apptec is an international leading open capability and technology platform company, which provides a full range of integrated laboratory R & D and production services from drug discovery, development to marketization for the global pharmaceutical and medical device fields With the purpose of taking research as the first task and customer as the center, Wuxi apptec helps global customers shorten the R & D cycle of drugs and medical devices and reduce the R & D cost through a cost-effective and efficient service platform The platform includes small molecule drug R & D and production, cell therapy and gene therapy R & D and production, medical device testing, etc it is carrying thousands of R & D and innovation projects from more than 3500 innovation partners from more than 30 countries around the world, and is committed to bringing the latest and best medicine and health products to patients around the world, so as to realize "no hard medicine, no hard disease to treat" ”Dream of For more information, please visit our website: www.wuxiapptec.com source: Wuxi apptec